Promising results of Providence-sponsored trial published in npj Breast Cancer

July 3, 2023 Earle A. Chiles Research Institute

Share this Article
Facebook
Twitter
LinkedIn

The final outcomes from a Providence Cancer Institute-sponsored phase Ib trial were published in npj Breast Cancer on June 21. The trial evaluated pembrolizumab, an immunotherapy, with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic triple-negative breast cancer. Both regimens achieved predetermined safety and efficacy outcomes. The study, “A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer,” was led by David B. Page, M.D., Providence Cancer Institute. npj Breast Cancer is an open access, multidisciplinary research journal dedicated to publishing leading-edge breast cancer research and treatment.

Read about the trial.

Breast cancer survivor, artist gives back to Providence

Providence Willamette Falls celebrates opening of new cancer center

Local grateful patient seeks spine specialist

After his chronic lower back pain suddenly worsened, a local grateful patient sought spine specialist Dr. M...

Of Bravery, Birth and Beauty

A young mother is tested when she receives a cancer diagnosis during pregnancy.

Most Recent Articles

Growing hope

Promising results of Providence-sponsored trial published in npj Breast Cancer

Previous Article

Next Article

Most Recent Articles

When a stroke robbed Lauren of her balance, the team on 4K – Providence Acute Rehabilitation Center – helped her regain what she lost with a little help from sunflowers, marigolds and little bugs.

The bariatric programs at Providence Little Company of Mary’s San Pedro and Torrance locations offer effective, long-term weight-loss solutions.

Providence South Division Cancer Institute earns national recognition as a top cancer program

Hospital program the only one recognized in Greater L.A. Area

More than 2,000 years ago, Hippocrates—the father of modern medicine—suggested that all diseases begin in the gut. With mounting evidence showing a connection between gut health and everything from au

Grounding allows us to use the earth’s negative electric charge to stabilize and rebalance our body’s accumulated positive charges. Contact with the vast supply of electrons on the earth’s surface—thi

Despite the sometimes dramatic improvements that have been made in other cancers, lung cancer survival has only slightly improved over the past several decades. Fortunately, that’s beginning to change

Rob Sears had been troubled by an increasingly erratic heartbeat for years. He finally found help from Dr. Shephal Doshi and a leading-edge minimally invasive procedure.

A special request for our patients and visitors – Farsi and Spanish translation further below:

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The team at the Adult and Pediatric Cochlear Implant Program, Dr. Courtney Voelker and Dr. Rebecca Lewis, restored Father Timothy McGowan’s hearing so he could get back to the work he loves.

Kadlec offering Prevention4ME for detection of breast and other cancers.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

In 2023, Providence Alaska contributed $265,000 to Catholic Social Services’ Medical Respite program, which provides recuperative living quarters for patients experiencing homelessness.

Learn why a proposed FSED is not right for our community.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.